Lophius Biosciences GmbH
Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.
The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.
With its T-Track® CMV leading product, based on T-activation® technology, Lophius offers a highly sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track® CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.
Lophius Biosciences GmbH was founded in 2002 as a spin-off company of the University of Regensburg in Bavaria. Closely linked to the university’s clinical facilities, the company focused on further development of innovate technology platforms for T cell-based diagnostic systems. Closing the first seed-financing in 2008 with the High-Tech Gründerfonds and Bayern Kapital, product development was pushed forward, followed by subsequent financing rounds with private and public investors to strengthen production, marketing and management activities.
In 2011, the company settled in the Technology Centre BioPark Regensburg to meet the needs for laboratory and office space, with its continuously growing team of scientists, technical assistants and managers. Today, Lophius successfully develops, manufactures and markets its leading product T-Track® CMV under ISO13485 quality standards. Together with industry and research partners, Lophius also performs various cooperation projects for the clinical validation of their immune monitoring tools.
Lophius patented technology platforms enable the development of T cell-based diagnostic solutions for multiple indications. With maximum flexibility in terms of read-out systems, it furthermore facilitates the evaluation and improvement of vaccines, biologics, drugs and the monitoring of therapy success.
The T-activation® Technology enhances the immune stimulatory capacity and immunogenicity of proteins to closely mimic natural uptake, processing and presentation of antigens. The Reverse T Cell Technology (RTT) is a novel strategy to distinguish between active and memory T cells for innovative diagnostics. Based on the RTT, Lophius is developing a diagnostic tuberculosis (TB) test, which can confirm TB infection and, importantly, can discriminate between active disease and latent infection.
Lophius Biosciences GmbH is an ISO13485- and Korea GMP-certified manufacturer.